Mark V. Roeder

Mark's representative transactions include:

Life Sciences IPOs and Follow-on Equity Offerings – Company Representation

• Ardelyx – US$60 million IPO and several follow-on equity offerings raising nearly US$350 million
• Ascendis Pharma – US$124 million IPO and several follow-on equity public offerings raising more than US$900 million
• CytomX Therapeutics – US$142 million follow-on equity public offering
• Intermune –convertible notes offerings raising US$276 million, and several follow-on equity public offerings US$860 million
• KYTHERA Biopharmaceuticals – US$80 million IPO and US$133 million follow-on offering
• Mirna Therapeutics – US$49 million IPO
• OncoMed Pharmaceuticals – US$87 million IPO  and US$51 million follow-on equity public offering
• Relypsa – US$78 million IPO and multiple follow-on equity public offerings raising nearly US$300 million
• Revolution Medicines – US$230 million follow-on equity public offering
• UNITY Biotechnology – US$85 million IPO

Life Sciences IPOs and Follow-on Equity Offerings – Underwriters Representation

• Aduro Biotech – US$136 million IPO
• Alios BioPharma – US$1.75 billion sale to Johnson & Johnson
• AveXis – several follow-on equity public offerings raising nearly US$750 million
• CytomX Therapeutics – US$92 million IPO

Life Sciences – M&A Transactions

• CV Therapeutics – US$1.5 billion sale to Gilead Sciences following a successful defense against a hostile bid by Astellas Pharma
• DVS Sciences – US$208 million sale to Fluidigm
• Envoy Therapeutics – US$140 million sale to Takeda Pharmaceutical
• KYTHERA Biopharmaceuticals – US$2.1 billion sale to Allergan
• Menlo Therapeutics – US$120 million IPO
• Modernizing Medicines – US$58 million acquisition of gMed
• Odonate Therapeutics – US$160 million initial public
• Pearl Therapeutics – US$1.15 billion sale to AstraZeneca
• Relypsa – US$1.53 billion sale to Galenica Group

Technology IPOs and Follow-on Offerings – Company Representation

• Integrated Device Technology – US$374 million convertible notes offering
• Mellanox Technologies – US$117 million IPO and follow-on public equity offering raising nearly US$100 million

Technology – M&A Transactions

• Greenplum – sale to EMC (confidential terms)
• Integrated Device Technology – US$1.7 billion merger with Integrated Circuit Systems
• Integrated Device Technology – US$7.1 billion sale to Reneasas
• Mellanox Technologies – US$6.9 billion sale to Nvidia, US$811 million purchase of EZ Chip, US$82 million purchase of Kotura, US$218 million purchase of Voltaire, and US$48 million purchase of IPtronics
• Netli – US$170 million sale to Akamai Technologies

Venture Financings

• Lead Investors’ counsel in hundreds of venture financings, including investments in: Carta, Segment.io, Lucid Software, Duo Security, Mulesoft, Verkada, Cloudera, ROBLOX, Zulily, Tableau Software, and Box